NN 2901
Alternative Names: NN-2901Latest Information Update: 20 Feb 2022
At a glance
- Originator Novelty Nobility
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinopathy of prematurity
Most Recent Events
- 20 Feb 2022 Early research in Retinopathy of prematurity in South Korea (Ophthalmic) before February 2022 (Novelty Nobility pipeline, February 2022)
- 20 Feb 2022 Preclinical trials in Retinopathy of prematurity in South Korea (Ophthalmic) (Novelty Nobility pipeline, February 2022)